Short-Term Treatment with Empagliflozin Resulted in Dehydration and Cardiac Arrest in an Elderly Patient with Specific Complications: A Case Report and Literature Review

Empagliflozin is a sodium-glucose cotransporter-2 inhibitor widely used in the treatment of diabetes mellitus and heart failure. Our case study involved a 68-year-old patient who was admitted to the hospital because of a cerebral infarction. The patient was simultaneously diagnosed with diabetes mel...

Full description

Saved in:
Bibliographic Details
Published in:Medicina (Kaunas, Lithuania) Lithuania), 2022-06, Vol.58 (6), p.815
Main Authors: Supakul, Sopak, Nishikawa, Yurika, Teramura, Masanori, Takase, Tetsuro
Format: Article
Language:English
Subjects:
Angina pectoris
Antidiabetics
Asian people
Cardiac arrest
Cardiopulmonary resuscitation
Carotid arteries
Case Report
Case reports
Clinical trials
CPR
Creatinine
dehydration
Diabetes
Drug dosages
Ejection fraction
Electrocardiography
Embolisms
empagliflozin
Glucose
Heart failure
Hospitalization
Hyperglycemia
Hyperkalemia
Insulin
Laboratories
Patients
Potassium
sodium-glucose cotransporter-2 (SGLT-2) inhibitor
Thrombosis
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Empagliflozin is a sodium-glucose cotransporter-2 inhibitor widely used in the treatment of diabetes mellitus and heart failure. Our case study involved a 68-year-old patient who was admitted to the hospital because of a cerebral infarction. The patient was simultaneously diagnosed with diabetes mellitus and heart failure, for which empagliflozin was initiated. However, food and fluid intake were reduced due to poor appetite. In addition to the side effects of empagliflozin, the patient developed severe dehydration and cardiac arrest. Careful assessment of dehydration and preventive water intake is recommended in elderly patients and those with neurological deficits, especially when receiving empagliflozin.
ISSN:1648-9144
1010-660X
1648-9144
DOI:10.3390/medicina58060815